impact factor
logo
 

Full Papers

 

Are pain severity and current pharmacotherapies associated with quality of life, work productivity, and healthcare utilisation for people with osteoarthritis in five large European countries?


1, 2, 3, 4, 5, 6, 7, 8, 9

 

  1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK. p.conaghan@leeds.ac.uk
  2. Kantar, NY, USA.
  3. Kantar, Tel Aviv, Israel.
  4. Pfizer Ltd., Budapest, Hungary.
  5. Pfizer Ltd., Surrey, UK.
  6. Eli Lilly and Company, Indianapolis, IN, USA.
  7. Pfizer Ltd., Groton, CT, USA.
  8. Pfizer Ltd., Groton, CT, USA.
  9. Pain Center, Cochin Hospital, Paris Descartes University, Paris, France.

CER13343
Full Papers

purchase article

PMID: 32896256 [PubMed]

Received: 19/03/2020
Accepted : 06/07/2020
In Press: 04/09/2020

Abstract

OBJECTIVES:
Although the osteoarthritis (OA) burden is well-recognised, the benefit of currently available OA pharmacological therapy is not clear. This study aimed to assess whether the impact of OA pain on health-related quality of life (HRQoL), work, and healthcare resource utilisation (HRU) differed by both pain severity and prescription medication status.
METHODS:
This cross-sectional study used pooled data from the 2016/2017 European National Health and Wellness Survey. Respondents with self-reported physician-diagnosed OA and pain were included. Outcomes examined included HRQoL, health utility, health status, work productivity and activity impairment, and HRU. Groups derived from self-reported pain severity and prescription medication use were compared using chi-square tests, analysis of variance, and generalised linear models controlling for socio-demographics, health behaviours, and health status.
RESULTS:
Respondents with OA (n=2417) reported mild (40.4%, of which 44.9% prescription-treated) and moderate to severe pain (59.6%, of which 54.0% prescription-treated). HRQoL, health utility, health status, and work and activity impairment were substantially worse among the moderate/severe pain prescription-treated group compared to the rest (e.g. SF-12v2 physical component score [PCS] for moderate/severe pain prescription-treated=34.5 versus mild pain prescription-treated =39.3, moderate/severe pain prescription-untreated=40.6, and mild pain prescription-untreated=45.6; p<0.01). HRU such as the mean number of emergency room visits for >6 months was higher in the prescription-treated groups (0.51–0.52, 95% CI 0.437–0.71) than the prescription-untreated groups (0.30–0.34, 95% CI 0.21–0.46; p<0.05).
CONCLUSIONS:
Persons with moderate to severe OA pain treated with available prescription medications have poor health status and HRQoL and increased HRU compared to those not receiving prescription medications.

Rheumatology Article

Rheumatology Addendum